The FDA outlined a pilot approach to expedite review of new drugs as the agency focuses on narrowing developmental timelines and improving U.S. competitiveness. The program is described as an expedited track that would let the agency move up to Phase 3 programs for selected candidates faster, aligning with broader pressure to close gaps versus China in drug development. The FDA’s plan was detailed as part of ongoing policy debates on how to structure faster decision-making while keeping regulatory standards intact. The agency also signaled it is eyeing up to 10 programs for the pilot, indicating limited initial scope. For biotech, the pilot’s practical impact will depend on how candidates qualify and which evidentiary packages are accepted to support earlier phase transitions and accelerated development plans.